Kemp Proteins, LLC

Frederick, MD Doing business as Kempbio

UEI
JMLEB78WL8B4
CAGE
5BCT2
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

FY2025 rankings
Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
5119 Pegasus Ct p, Frederick, MD 21704, USA
Founded
2008
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $33,608
FY2024 -$9,820
FY2023 $149,190

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Contract subawards

Prime contractor Prime award Amount Awarded
Sterling Computers Corporation DEVELOPMENT OF ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS) FOR NINDS NIH BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROJECT Manufacture full-length recombinant… 75N95023F00001 $47,965

Similar vendors

About the company

Kemp Proteins, LLC, doing business as Kempbio, is a Frederick, Maryland-based small disadvantaged business manufacturer that specializes in gene-to-protein bioservices and biological research support. The company is registered in SAM.gov as a partnership or limited liability partnership and provides a comprehensive range of services to support federal biomedical research, vaccine development, and infectious disease studies. Kempbio has established itself as a reliable provider of specialized immunological materials and laboratory services to multiple federal agencies, leveraging expertise across protein expression, gene synthesis, molecular cloning, monoclonal antibody production, and viral-like particle production.

Kempbio's prime federal contract awards demonstrate extensive experience delivering sophisticated biological services across multiple government agencies. The company has received purchase orders and delivery orders from the National Institute of Allergy and Infectious Diseases (NIAID) totaling approximately $61,000 for gene synthesis, cloning, plasmid generation, gene expression screening, construct design, and baculovirus production services, with performance periods spanning from 2021 through 2023. The Food and Drug Administration awarded Kempbio approximately $95,600 in purchase orders for monoclonal antibody production and baculovirus protein expression services, with the monoclonal antibody production contract designated as a total small business set-aside with performance extending through September 2027. The National Institute of Dental and Craniofacial Research awarded a $28,200 purchase order for production, purification, and analysis of viral-like particle services. Most recently, the Defense Health Agency issued a $40,000 delivery order on August 1, 2025, for hybridoma production services scheduled for completion by September 28, 2026. Additionally, Kempbio has served as a subcontractor to prime contractors Battelle Memorial Institute and Mriglobal, performing gene synthesis, cloning, and recombinant protein manufacturing work supporting specialized biodefense and research initiatives. The cumulative value of Kempbio's documented prime contracts exceeds $300,000, reflecting the company's consistent performance across multiple federal research programs.

Kempbio holds a significant single-award Blanket Purchase Agreement (BPA) with the Office of Logistics and Acquisition Operations valued at up to $10,000,000, with a period of performance through August 31, 2026. This BPA, awarded on August 1, 2023, was structured to facilitate recurring procurement of biological materials, animal testing services, and laboratory and testing services on an as-needed basis through task order issuance. The BPA represents Kempbio's most substantial federal contract vehicle and underscores the company's capacity to support sustained biomedical research programs across federal agencies. The agreement's broad scope covering biological materials and comprehensive testing services aligns with Kempbio's core competencies in gene-to-protein bioservices and positions the company as a standing source for federal agencies requiring specialized biological research support and materials on a recurring basis.

Quick answers

Is Kemp Proteins, LLC registered in SAM.gov?

Yes. Kemp Proteins, LLC's SAM.gov registration is active through June 11, 2027.

What is Kemp Proteins, LLC's CAGE code?

Kemp Proteins, LLC's CAGE code is 5BCT2, and its Unique Entity ID (UEI) is JMLEB78WL8B4.

How much has Kemp Proteins, LLC received in federal contracts?

Federal contracts obligated $33,608 to Kemp Proteins, LLC in fiscal year 2025 and $172,978 in fiscal years 2023 through 2027.

How does Kemp Proteins, LLC rank among federal contractors?

Kemp Proteins, LLC ranked #72 in NAICS 325414 in FY2025.

What is Kemp Proteins, LLC's most recent federal award?

Kemp Proteins, LLC's most recent federal contract award is Hybridoma production (HT942525FE003), from Defense Health Agency, on August 1, 2025.

On GovTribe

See Kemp Proteins, LLC's full federal record

  • Federal contract awards
  • IDV awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe